This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection.

Jeffrey A. Lieberman, M.D.; L. Fredrik Jarskog, M.D.; and Dolores Malaspina, M.D., M.S.P.H.

Published: June 15, 2006

Article Abstract

Click to enlarge page

Jeffrey A. Lieberman, M.D., opened with a brief overview of the natural history of schizophrenia. When Emil Kraepelin1 initially distinguished dementia praecox, which later came to be known as schizophrenia, from general insanity, he did so based not on patients’ symptoms or on any particular aspect of the clinical presentation but on the longitudinal course of the illness, particularly the clinical deterioration that was noticed in patients. Patients with schizophrenia in the early part of the twentieth century, when Kraepelin was performing his research, had no treatment available to them and thus were forced to suffer the consequences of their illness.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: